Literature DB >> 2514140

Release of cytokines during generation of lymphokine-activated killer (LAK) cells by IL-2.

G A Limb1, A Meager, J Woolley, M Wadhwa, J Biggerstaff, K A Brown, R A Wolstencroft.   

Abstract

Supernatants of IL-2-activated mononuclear cells (MNC) that displayed an optimal lymphokine-activated killer (LAK) cell activity at 48-72 hr in culture were found to contain increased levels of tumour necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha) and interferon-gamma (IFN-gamma) when compared with supernatants from mononuclear cells cultured in the absence of IL-2. The concentration of TNF alpha and IL-1 alpha produced by MNC at 24 hr was either increased or maintained by extending the cultures to 96 hr. In contrast, TNF beta was only detected at very low levels after 72-96 hr culture, irrespective of whether IL-2 was present or absent. Optimal concentrations of IL-2 needed to induce maximum release of TNF alpha, IL-1 alpha and IFN-gamma by MNC varied among different individuals. Enriched populations of lymphocytes secreted higher levels of all measured cytokines upon activation with IL-2 in contrast to untreated cells. Supernatants from purified monocyte preparations contained high concentrations of TNF alpha and IL-1 alpha regardless of the presence of IL-2 in the cell cultures. This work suggests that in addition to the generation of LAK cell activity, by promoting the release of other cytokines with potential anti-tumoricidal activity, IL-2 may be amplifying cell-mediated cytotoxicity, which is associated with protection against neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2514140      PMCID: PMC1385540     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  20 in total

1.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

2.  Augmentation of natural and antibody-dependent cell-mediated cytotoxicity by pure human leukocyte interferon.

Authors:  R B Herberman; J R Ortaldo; M Rubinstein; S Pestka
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

3.  Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.

Authors:  B T Gemlo; M A Palladino; H S Jaffe; T P Espevik; A A Rayner
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

4.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon.

Authors:  B D Williamson; E A Carswell; B Y Rubin; J S Prendergast; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

5.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

Authors:  G E Nedwin; L P Svedersky; T S Bringman; M A Palladino; D V Goeddel
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

6.  Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity.

Authors:  P W Gray; B B Aggarwal; C V Benton; T S Bringman; W J Henzel; J A Jarrett; D W Leung; B Moffat; P Ng; L P Svedersky
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  APAAP labelling of blood and bone-marrow samples for phenotyping leukaemia.

Authors:  W N Erber; L C Mynheer; D Y Mason
Journal:  Lancet       Date:  1986-04-05       Impact factor: 79.321

9.  Response of resting human peripheral blood natural killer cells to interleukin 2.

Authors:  G Trinchieri; M Matsumoto-Kobayashi; S C Clark; J Seehra; L London; B Perussia
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more
  14 in total

1.  Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy.

Authors:  G A Limb; A H Chignell; W Green; F LeRoy; D C Dumonde
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

2.  Evidence of chronic inflammation in retina excised after relaxing retinotomy for anterior proliferative vitreoretinopathy.

Authors:  G A Limb; A H Chignell; H Woon; W Green; C J Cole; D C Dumonde
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-04       Impact factor: 3.117

3.  Selective up-regulation of human granulocyte integrins and complement receptor 1 by cytokines.

Authors:  G A Limb; A S Hamblin; R A Wolstencroft; D C Dumonde
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

4.  Operative stress potentiates the inductivity of membrane associated lymphotoxin (mLT) on lymphokine activated killer (LAK) cells in vitro.

Authors:  A Horiuchi; Y Abe; M Miyake; K Kimura; Y Osuka; S Kimura
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  The CySF-L2 factor from dialysable human leucocyte extract activates natural killer cytotoxicity by induction of interferon gamma.

Authors:  I Doelker; F A Anderer
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Use of recombinant interleukin-2 to enhance adoptive transfer of resistance to Listeria monocytogenes infection.

Authors:  M Haak-Frendscho; C J Czuprynski
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  Proliferative vitreoretinopathy: an examination of the involvement of lymphocytes, adhesion molecules and HLA-DR antigens.

Authors:  G A Limb; W A Franks; K R Munasinghe; A H Chignell; D C Dumonde
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-06       Impact factor: 3.117

8.  IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.

Authors:  C Bello-Fernandez; P Oblakowski; A Meager; A S Duncombe; D M Rill; A V Hoffbrand; M K Brenner
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

9.  Role of membrane-associated lymphotoxin (mLT) in the killing activity of lymphokine-activated killer (LAK) cells towards various tumour cell lines.

Authors:  A Horiuchi; Y Abe; M Miyake; K Kimura; Y Hitsumoto; N Takeuchi; S Kimura
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

10.  Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis.

Authors:  J Hauer; F A Anderer
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.